COST-EFFECTIVENESS OF TEPOTINIB FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER HARBORING METEX14 SKIPPING ALTERATIONS IN SPAIN

被引：0
|
作者：
Arriola, E. [1 ]
Batteson, R. [2 ]
Hook, E. [2 ]
Wheat, H. [2 ]
Vioix, H. [3 ]
Morros, M. [4 ]
Aguila, M. [4 ]
de los Santos Real, H. [5 ]
Soberon S, Fernandez [5 ]
Brines, M. [5 ]
Vazquez, S. [6 ]
机构：
[1] Hosp Mar, Barcelona, Spain
[2] Delta Hat Ltd, Nottingham, England
[3] Merck KGaA, Healthcare Business, Darmstadt, HE, Germany
[4] Adelphi Targis, Barcelona, Spain
[5] Merck SLU, Madrid, Spain
[6] Hosp Univ Lucus Augusti, Lugo, Spain
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE146
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 50 条
  • [1] TEPOTINIB FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER HARBORING METEX14 SKIPPING ALTERATIONS: A US COST-EFFECTIVENESS ANALYSIS
    Yang, M.
    Sachdev, R.
    Stargardter, M.
    Tosh, J.
    Vioix, H.
    VALUE IN HEALTH, 2022, 25 (07) : S365 - S365
  • [2] US health utility in advanced non-small cell lung cancer (NSCLC) patients harboring MET exon 14 (METex14) skipping mutations treated with tepotinib
    Paik, Paul K.
    Yang, Mo
    Knowles, Emma
    Hatswell, Anthony
    Vioix, Helene
    Liu, Frank Xiaoqing
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [3] Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States
    Stargardter, Matthew
    McBride, Ali
    Tosh, Jon
    Sachdev, Rameet
    Yang, Mo
    Ambavane, Apoorva
    Mittal, Madhav
    Vioix, Helene
    Liu, Frank Xiaoqing
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 816 - 827
  • [4] Case report: Response to tepotinib in Chinese non-small cell lung cancer patients harboring METex14 skipping with varying features
    Meng, Yan
    Zhou, Weiping
    Li, Chenping
    Zhou, Xiangjie
    Li, Xiao
    Li, Liang
    Fu, Qiye
    Huang, Jue
    Yue, Yali
    Shen, Xuguang
    Yang, Lijing
    Wang, Meiqing
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [5] BUDGET IMPACT ANALYSIS OF TEPOTINIB IN ENGLAND FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) HARBORING MET EXON 14 (METEX14) SKIPPING
    McLean, T.
    Alexopoulos, S.
    Hook, E.
    Batterson, R.
    Vioix, H.
    VALUE IN HEALTH, 2022, 25 (12) : S143 - S143
  • [6] MODELING THE COST-EFFECTIVENESS IN A SUBPOPULATION: TEPOTINIB VERSUS CHEMOIMMUNOTHERAPY (C plus IO) IN UNTREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING MET EXON 14 (METEX14) SKIPPING
    Batteson, R.
    Vioix, H.
    Wheat, H.
    Battershill, W.
    VALUE IN HEALTH, 2023, 26 (12) : S122 - S122
  • [7] MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF TEPOTINIB WITH CAPMATINIB IN PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) WITH MET EXON 14 (METEX14) SKIPPING
    Paik, P.
    Pfeiffer, B.
    Vioix, H.
    Postma, M. J.
    VALUE IN HEALTH, 2022, 25 (12) : S28 - S28
  • [8] Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
    Reinmuth, N.
    Popat, S.
    Paz-Ares, L.
    Knowles, E.
    Hatswell, A.
    McLean, T.
    Adrian, S.
    Gaumond, B.
    Vioix, H.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S985 - S986
  • [9] Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK
    Batteson, Rachael
    Hook, Emma
    Wheat, Hollie
    Hatswell, Anthony J.
    Vioix, Helene
    Mclean, Thomas
    Alexopoulos, Stamatia Theodora
    Baijal, Shobhit
    Paik, Paul K.
    TARGETED ONCOLOGY, 2024, 19 (02) : 191 - 201
  • [10] Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK
    Rachael Batteson
    Emma Hook
    Hollie Wheat
    Anthony J. Hatswell
    Helene Vioix
    Thomas McLean
    Stamatia Theodora Alexopoulos
    Shobhit Baijal
    Paul K. Paik
    Targeted Oncology, 2024, 19 : 191 - 201
12345